Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

5(50.0%)

Phase 2

3(30.0%)

Phase 1

2(20.0%)

10Total

Phase 3(5)

Phase 2(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01341548Phase 3Not Yet Recruiting

Civamide Nasal Solution for Cluster Headache

Role: lead

NCT01886313Phase 2Terminated

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

Role: lead

NCT00845923Phase 2Completed

Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia

Role: lead

NCT02116244Phase 2Completed

Civamide Nasal Solution for the Treatment of Dry Eye

Role: lead

NCT00033839Phase 3Completed

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

Role: lead

NCT00995306Phase 3Completed

Evaluating the Safety and Efficacy Civamide in Osteoarthritis (OA) of the Knee(s)

Role: lead

NCT00069082Phase 3Completed

Intranasal Civamide for Episodic Cluster Headache

Role: lead

NCT00802217Phase 1Terminated

Oral Civamide Safety, Tolerability First in Human Study

Role: lead

NCT00758433Phase 1Completed

Civamide Patch Safety, Tolerability and PK Study

Role: lead

NCT00077935Phase 3Completed

Civamide in OA of the Knee(s)

Role: lead

All 10 trials loaded